Research programme: interleukin 1 beta inhibitors - Opsona

Drug Profile

Research programme: interleukin 1 beta inhibitors - Opsona

Alternative Names: IL1-ß inhibitor - Opsona

Latest Information Update: 03 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Opsona Therapeutics
  • Class Small molecules
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Research Inflammation

Most Recent Events

  • 03 Feb 2017 The interleukin 1 beta inhibitor research programme is still under early research for Inflammation in Ireland (Opsona Therapeutics pipeline, February 2017)
  • 03 Feb 2017 Research programme: interleukin 1 beta inhibitors - Opsona is available for licensing/partnering as of 03 Feb 2017.
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Ireland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top